Making Advanced Therapies Affordable and Accessible
Two Strategic Approaches
Bibliographic Data
| ID | 19516451 |
|---|---|
| Authors | Ubaka Ogbogu (0000-0001-7764-6799, Faculty of Law University of Alberta Edmonton Alberta Canada, corresponding author), Lauren Albrecht (0000-0002-6088-291X, Faculty of Law University of Alberta Edmonton Alberta Canada) |
| Year | 2026 |
| Volume | 26 |
| Issue | 1 |
| Pages | 66-78 |
| Publication date | 2026-03-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Developing World Bioethics (JOURNAL) |
| Journal identifiers | ISSN: 1471-8731 • E-ISSN: 1471-8847 |
| Publisher | Wiley (PUBLISHER • GB) |
| DOI | 10.1111/dewb.70004 |
| PMID | 40928580 |
| OpenAlex | W4414085393 |
| Language | EN |
| Citations received | 1 |
| References cited | 78 |
This article explores two complementary strategies for addressing the affordability and access challenges facing advanced therapies. As high development costs and limited market access have led to the withdrawal of several therapies, the article examines how these barriers create ‘valleys of death’ that prevent innovation from reaching patients. Through the case of Glybera and other examples, it outlines a rehabilitative approach focused on reforming current systems through improved reimbursement schemes, regulatory streamlining, and more efficient manufacturing. It also presents a transformative approach that embeds affordability and access from the beginning of the research and development process, encouraging local innovation, equitable intellectual property practices, and adaptive regulatory frameworks. Lessons from the COVID‐19 vaccine experience demonstrate the real‐world potential of these strategies to ensure that promising therapies are not only developed, but also equitably delivered worldwide
Access to medicines · Expanded access · Intellectual property · Market access · Reimbursement · Transformative learning · Biomedical Ethics and Regulation · Health Systems, Economic Evaluations, Quality of Life · Pharmaceutical Economics and Policy
Covid-19 Vaccination in Lower-Middle Income Countries
Escalating costs of innovative medicines
Covax and the many meanings of sharing
Pandemic preparedness and response
Negotiating public-health intellectual property licensing agreements to increase access to health technologies
Regenerative medicine regulatory policies
Lessons learned from the Canadian Fabry Disease Initiative for future risk-sharing and managed access agreements for pharmaceutical and advanced therapies in Canada
Price regulation and competition among on-patent anticancer drugs in Italy
Evidence on the effectiveness of policies promoting price transparency - A systematic review
Updating the WHO target product profile for next-generation Mycobacterium tuberculosis drug susceptibility testing at peripheral centres
Which roads lead to access? A global landscape of six Covid-19 vaccine innovation models
A systematic review of pooled procurement of medicines and vaccines
Intellectual property licensing of therapeutics during the Covid-19 crisis
El Fondo Rotatorio para el acceso a las vacunas de la Organización Panamericana de la Salud
Suitability of two WHO research and development initiatives for Covid-19 to promote equitable innovation
Global inequities in access to Covid-19 health products and technologies
| Citations per year | 1 |
|---|---|
| Citation span | 2025 - 2025 (1) |
| Highly cited | No |